{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:43:36Z","timestamp":1790019816211,"version":"4.0.1"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T00:00:00Z","timestamp":1400112000000},"content-version":"vor","delay-in-days":865,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Laboratory Analysis"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:p>Our purpose is to evaluate the predictive value of the genetic polymorphisms of Excision repair cross\u2010complementing group 1 (ERCC1) and xeroderma pigmentosum group D\/excision repair cross\u2010complementing group 2 (XPD\/ERCC2) in patients with advanced colorectal cancer receiving oxaliplatin\u2010based chemotherapy, and we performed a meta\u2010analysis in order to obtain a more precise estimation for a more optimizing individual chemotherapy. The relevant cohort studies were identified by searching the electronic databases of MEDLINE, EMBASE, and CNKI. We used \u2018\u2018colorectal,\u2019\u2019 \u2018\u2018cancer,\u2019\u2019 \u2018\u2018carcinoma,\u2019\u2019 \u2018\u2018ERCC1,\u2019\u2019 \u2018\u2018XPD or ERCC2,\u2019\u2019 \u2018\u2018polymorphism,\u2019\u2019 \u2018\u2018oxaliplatin,\u2019\u2019 \u2018\u2018treatment,\u2019\u2019 or \u2018\u2018chemotherapy\u2019\u2019 as key words. Inclusion criteria were patients with advanced colorectal cancer receiving oxaliplatin\u2010based chemotherapy, evaluation of polymorphism of ERCC1 and XPD\/ ERCC2, and overall response rate (ORR). In this meta\u2010analysis, a total of seven studies were selected according to the inclusion criteria. Five studies investigated ERCC1 codon 118 polymorphisms and three studies evaluated XPD\/ERCC2 codon 751 polymorphisms. For ERCC1 codon C118T polymorphism, the ORR to oxaliplatin\u2010based chemotherapy in patients with C\/C wild genotype was 77.27% and it was 69.30% for C\/T and T\/T variant genotype. The pooled odds ratio (OR) for C\/C wild\u2010type vs. C\/T and T\/T genotype was 1.11 (95% CI, 0.86\u20131.42; <jats:italic>P<\/jats:italic> = 0.42). For XPD\/ERCC2 Lys751Gln polymorphism, the response rate was 86.58 and 67.57% in patients with the A\/A and either one or two C alleles (A\/C or C\/C) respectively, and the pooled OR was 1.15 (95% CI, 1.01\u20131.30; <jats:italic>P<\/jats:italic> = 0.03). Furthermore, we chose subgroup analysis in order to find the difference between the Caucasian and Asian ethnicity. The results indicated that Oxaliplatin sensitivity was significantly associated with ERCC1 C118T polymorphism in Asian people. XPD\/ERCC2 Lys751Gln polymorphism had the predictive value especially for the patients from the America and Europe.<\/jats:p>","DOI":"10.1002\/jcla.20494","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T13:35:39Z","timestamp":1400160939000},"page":"10-15","source":"Crossref","is-referenced-by-count":12,"title":["ERCC1 and XPD\/ERCC2 Polymorphisms\u2019 Predictive Value of Oxaliplatin\u2010Based Chemotherapies in Advanced Colorectal Cancer has an Ethnic Discrepancy: A Meta\u2010analysis"],"prefix":"10.1002","volume":"26","author":[{"given":"Xiaobo","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Hygiene Toxicology China Medical University  Shenyang People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hygiene Toxicology China Medical University  Shenyang People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihong","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hygiene Toxicology China Medical University  Shenyang People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahar","family":"van der Straaten","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy &amp; Toxicology Leiden University Medical Center  Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery The Fourth Affiliated Hospital China Medical University  Shenyang People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,5,15]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00012514"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.126"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032709"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.046"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060040-00005"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00219-0"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1033.2002.02888.x"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-9084(99)80034-0"},{"key":"e_1_2_5_11_1","first-page":"817","article-title":"Research progress about chemotherapeutic effect and prognosis of excision repair cross\u2014Complementing 1 on malignancies","volume":"17","author":"Shusheng Z","year":"2010","journal-title":"Pract Prev Med"},{"key":"e_1_2_5_12_1","first-page":"109","article-title":"Research progress about correlation of XPD\/ ERCC2 polymorphism with sensitivity to diseases","volume":"33","author":"Yulan J","year":"2007","journal-title":"Ind Health Occup Dis"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9443-1"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.01031.x"},{"key":"e_1_2_5_15_1","first-page":"1068","article-title":"Genetic polymorphisms of ERCC1 and XRCC1 are correlated with the TTP of advanced colorectal cancer patients treated with oxaliplatin\u2010based chemotherapy","volume":"35","author":"Jun L","year":"2008","journal-title":"Chin Clin Oncol"},{"key":"e_1_2_5_16_1","first-page":"1329","article-title":"Genetic polymorphism of ERCC1 and XRCC1 correlated with response to oxaliplatin based chemotherapy in advanced colorectal cancer","volume":"15","author":"Jun L","year":"2008","journal-title":"Chin J Cancer Prev Treat"},{"key":"e_1_2_5_17_1","first-page":"623","article-title":"Research on the clinical outcome of advanced colorectal cancer treated with oxaliplatin influenced by ERCC1 gene polymorphism in peripheral blood","volume":"13","author":"Hua L","year":"2008","journal-title":"Chin Clin Oncol"},{"key":"e_1_2_5_18_1","first-page":"261","article-title":"The expression of ERCC1 in the tissue of colon carcinoma and its clinical significance","volume":"24","author":"Qiong Z","year":"2009","journal-title":"Pract J Cancer"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.23.4298"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000113534"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03556.x"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.03.025"},{"key":"e_1_2_5_23_1","first-page":"216","article-title":"Correlation of XPD\/ERCC2 polymorphism with clinical sensitivity to oxaliplatin\u2010based chemotherapy in advanced colorectal cancer","volume":"24","author":"Jian G","year":"2009","journal-title":"Med J Qilu"},{"key":"e_1_2_5_24_1","first-page":"1186","article-title":"The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin\u2010based chemotherapy in metastatic colorectal cancer","volume":"280","author":"Liang J","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp336"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10330-008-0086-z"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604671"},{"key":"e_1_2_5_28_1","first-page":"8654","article-title":"A xeroderma pigmentosum group d gene polymorphism predicts clinical outcome to platinum\u2010based chemotherapy in patients with advanced colorectal cancer","volume":"61","author":"Park DJ","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01186.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1363"},{"key":"e_1_2_5_31_1","first-page":"162","article-title":"ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum\u2010based chemotherapy","volume":"1","author":"Park DJ","year":"2003","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_5_32_1","first-page":"1513","article-title":"Polymorphisms in DNA repair genes and associations with cancer risk","volume":"11","author":"Goode EL","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.309"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2169"}],"container-title":["Journal of Clinical Laboratory Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcla.20494","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.20494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T17:21:50Z","timestamp":1696353710000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcla.20494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/jcla.20494"],"URL":"https:\/\/doi.org\/10.1002\/jcla.20494","archive":["Portico"],"relation":{},"ISSN":["0887-8013","1098-2825"],"issn-type":[{"value":"0887-8013","type":"print"},{"value":"1098-2825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}